By Darren Smith, Weekend Contributor
Turing garnered infamy for the 5000 percent price increase of Daraprim, a $13.50 medication indicated for patients requiring treatment of Toxoplasma gondii–an opportunistic pathogen afflicting the immune-compromised such as AIDS patients. Monthly treatment cost now associated with the drug can be upwards of seventy-five thousand dollars. See previous articles HERE and HERE.
Interim CEO Ron Tiles thanked the 32-year-old for “helping us build Turing Pharmaceuticals into the dynamic research-focused company it is today.”